scholarly journals Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 641
Author(s):  
Dashuai Zhu ◽  
Ke Cheng
Keyword(s):  
Heart Failure ◽  
Future Research ◽  
Cardiac Cell ◽  
Cellular Mechanisms ◽  
Heart Repair ◽  
Fibrotic Scar ◽  
Cardiac Cell Therapy ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Normal Cardiac Function

Cardiovascular disease (CVD) is still the leading cause of death worldwide. Coronary arteryocclusion, or myocardial infarction (MI) causes massive loss of cardiomyocytes. The ischemia areais eventually replaced by a fibrotic scar. From the mechanical dysfunctions of the scar in electronictransduction, contraction and compliance, pathological cardiac dilation and heart failure develops.Once end-stage heart failure occurs, the only option is to perform heart transplantation. The sequentialchanges are termed cardiac remodeling, and are due to the lack of endogenous regenerativeactions in the adult human heart. Regenerative medicine and biomedical engineering strategies havebeen pursued to repair the damaged heart and to restore normal cardiac function. Such strategiesinclude both cellular and acellular products, in combination with biomaterials. In addition, substantialprogress has been made to elucidate the molecular and cellular mechanisms underlying heartrepair and regeneration. In this review, we summarize and discuss current therapeutic approachesfor cardiac repair and provide a perspective on novel strategies that holding potential opportunitiesfor future research and clinical translation.

Localization of endothelial nitric oxide synthase in the normal and failing human atrial myocardium

1996 ◽  
Vol 54 ◽  
pp. 786-787
Author(s):  
Chi-Ming Wei ◽  
Margarita Bracamonte ◽  
Shi-Wen Jiang ◽  
Richard C. Daly ◽  
Christopher G.A. McGregor ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Nitric Oxide Synthase ◽  
Endothelial Nitric Oxide Synthase ◽  
Cardiac Tissues ◽  
Mammalian Tissues ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide

Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also may modulate cardiomyocyte inotropism and growth via increasing cGMP. While endothelial nitric oxide synthase (eNOS) isoforms have been detected in non-human mammalian tissues, expression and localization of eNOS in the normal and failing human myocardium are poorly defined. Therefore, the present study was designed to investigate eNOS in human cardiac tissues in the presence and absence of congestive heart failure (CHF).Normal and failing atrial tissue were obtained from six cardiac donors and six end-stage heart failure patients undergoing primary cardiac transplantation. ENOS protein expression and localization was investigated utilizing Western blot analysis and immunohistochemical staining with the polyclonal rabbit antibody to eNOS (Transduction Laboratories, Lexington, Kentucky).

562 The clinical improvement of end-stage heart failure is not accompanied by correction of anemia

2006 ◽  
Vol 5 (1) ◽  
pp. 126-126
Author(s):  
S DRAKOS ◽  
E KALDARA ◽  
M BONIOS ◽  
D KARAGEORGOPOULOS ◽  
C PIERRAKOS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Improvement ◽  
End Stage Heart Failure ◽  
End Stage

Vitamin D deficiency is an independent predictor for anemia in end-stage heart failure

2011 ◽  
Vol 59 (S 01) ◽  
Author(s):  
A Zittermann ◽  
A Jungvogel ◽  
S Prokop ◽  
U Fuchs ◽  
U Schulz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Independent Predictor ◽  
End Stage Heart Failure ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document